Literature DB >> 17699836

Quality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis/Hib combination vaccines.

Philippe A Denoël1, David Goldblatt, Isabel de Vleeschauwer, Jeanne-Marie Jacquet, Michael E Pichichero, Jan T Poolman.   

Abstract

It has been repeatedly observed that mixing Haemophilus influenzae type b (Hib) conjugate vaccines with acellular pertussis-containing vaccines (diphtheria-tetanus-acellular pertussis [DTPa]) resulted in a reduced magnitude of the anti-polyriboseribitolphosphate antibody response compared to that obtained when Hib vaccines were administered separately and not mixed. Nevertheless, the quality and functionality of the immune responses have been shown to be the same. With the purpose of investigating the quality of the anti-Hib immune responses that are elicited under different vaccination regimens, we report here four primary and booster-based pediatric clinical trials in which Hib vaccine was either mixed with DTPa or diphtheria-tetanus-whole-cell pertussis (DTPw)-based vaccines or was coadministered. Our results show that avidity maturation of the antibodies was lower when primary vaccination involved DTPa mixed with Hib compared to when DTPa and Hib were coadministered. No such difference was observed between mixed and separately administered Hib when associated with DTPa-hepatitis B virus-inactivated poliovirus or DTPw-based vaccines. All different combinations and regimens elicited the same opsonophagocytic and bactericidal activity as well as the same ability to protect in a passive infant rat protection assay. The functional activity of mixed DTPa-based and Hib vaccines was similar to that of mixed DTPw-based/Hib combinations. In conclusion, in vitro and in vivo data as well as postmarketing vaccine effectiveness data attest to the ability of DTPa-based/Hib combination vaccines to effectively prevent Hib-induced disease in children.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17699836      PMCID: PMC2168112          DOI: 10.1128/CVI.00154-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  33 in total

1.  Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis.

Authors:  J McVernon; N Andrews; M P E Slack; M E Ramsay
Journal:  Lancet       Date:  2003-05-03       Impact factor: 79.321

2.  Conjugate Hib vaccines.

Authors:  Mark Steinhoff; David Goldblatt
Journal:  Lancet       Date:  2003-02-01       Impact factor: 79.321

3.  Immunity to Haemophilus influenzae type b in young adults: correlation of bactericidal and opsonizing activity of serum with antibody to polyribosylribitol phosphate and lipooligosaccharide before and after vaccination.

Authors:  D Musher; A Goree; T Murphy; A Chapman; J Zahradnik; M Apicella; R Baughn
Journal:  J Infect Dis       Date:  1986-12       Impact factor: 5.226

4.  The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b.

Authors:  P Anderson
Journal:  J Infect Dis       Date:  1984-06       Impact factor: 5.226

5.  The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b.

Authors:  H Käyhty; H Peltola; V Karanko; P H Mäkelä
Journal:  J Infect Dis       Date:  1983-06       Impact factor: 5.226

6.  Haemophilus influenzae type b disease: impact and effectiveness of diphtheria-tetanus toxoids-acellular pertussis (-inactivated poliovirus)/H. influenzae type b combination vaccines.

Authors:  H J Schmitt; R von Kries; B Hassenpflug; M Hermann; A Siedler; W Niessing; R Clemens; J Weil
Journal:  Pediatr Infect Dis J       Date:  2001-08       Impact factor: 2.129

7.  A new DTPa-HBV-IPV vaccine co-administered with Hib, compared to a commercially available DTPw-IPV/Hib vaccine co-administered with HBV, given at 6, 10 and 14 weeks following HBV at birth.

Authors:  R Gylca; V Gylca; O Benes; A Melnic; V Chicu; C Weisbecker; P Willems; A Kaufhold
Journal:  Vaccine       Date:  2000-11-22       Impact factor: 3.641

8.  A high degree of natural immunologic priming to the capsular polysaccharide may not prevent Haemophilus influenzae type b meningitis.

Authors:  P Anderson; D L Ingram; M E Pichichero; G Peter
Journal:  Pediatr Infect Dis J       Date:  2000-07       Impact factor: 2.129

9.  Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction.

Authors:  Caroline L Trotter; Nick J Andrews; Edward B Kaczmarski; Elizabeth Miller; Mary E Ramsay
Journal:  Lancet       Date:  2004 Jul 24-30       Impact factor: 79.321

10.  Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method.

Authors:  Mary E Ramsay; Jodie McVernon; Nick J Andrews; Paul T Heath; Mary P Slack
Journal:  J Infect Dis       Date:  2003-07-31       Impact factor: 5.226

View more
  17 in total

1.  Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals.

Authors:  Joseph G Dauner; Yuanji Pan; Allan Hildesheim; Troy J Kemp; Carolina Porras; Ligia A Pinto
Journal:  Mol Cell Probes       Date:  2012-01-18       Impact factor: 2.365

2.  Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine.

Authors:  Joseph G Dauner; Yuanji Pan; Allan Hildesheim; Clayton Harro; Ligia A Pinto
Journal:  Vaccine       Date:  2010-06-17       Impact factor: 3.641

3.  Influence of maternal vaccination against diphtheria, tetanus, and pertussis on the avidity of infant antibody responses to a pertussis containing vaccine in Belgium.

Authors:  Raïssa Nadège Caboré; Kirsten Maertens; Alexandre Dobly; Elke Leuridan; Pierre Van Damme; Kris Huygen
Journal:  Virulence       Date:  2017-02-22       Impact factor: 5.882

4.  Effects of Serial Skin Testing with Purified Protein Derivative on the Level and Quality of Antibodies to Complex and Defined Antigens in Mycobacterium bovis-Infected Cattle.

Authors:  W Ray Waters; Mitchell V Palmer; Molly R Stafne; Kristin E Bass; Mayara F Maggioli; Tyler C Thacker; Rick Linscott; John C Lawrence; Jeffrey T Nelson; Javan Esfandiari; Rena Greenwald; Konstantin P Lyashchenko
Journal:  Clin Vaccine Immunol       Date:  2015-04-08

5.  Risk of invasive Haemophilus influenzae type b (Hib) disease in adults with secondary immunodeficiency in the post-Hib vaccine era.

Authors:  Eli B Nix; Nicole Hawdon; Sean Gravelle; Birubi Biman; Malcolm Brigden; Saleem Malik; William McCready; Garry Ferroni; Marina Ulanova
Journal:  Clin Vaccine Immunol       Date:  2012-03-07

Review 6.  Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.

Authors:  Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

7.  Fast, antigen-saving multiplex immunoassay to determine levels and avidity of mouse serum antibodies to pertussis, diphtheria, and tetanus antigens.

Authors:  Rachel M Stenger; Mieke Smits; Betsy Kuipers; Sabine F M Kessen; Claire J P Boog; Cécile A C M van Els
Journal:  Clin Vaccine Immunol       Date:  2011-02-16

8.  Combination of two candidate subunit vaccine antigens elicits protective immunity to ricin and anthrax toxin in mice.

Authors:  David J Vance; Yinghui Rong; Robert N Brey; Nicholas J Mantis
Journal:  Vaccine       Date:  2014-12-02       Impact factor: 3.641

Review 9.  How to design effective vaccines: lessons from an old success story.

Authors:  Nabil Ahmed; Stephen Gottschalk
Journal:  Expert Rev Vaccines       Date:  2009-05       Impact factor: 5.217

10.  Assessment of antibody level and avidity against Bordetella pertussis in a cohort of Egyptian individuals aged 1-18 years.

Authors:  Nihal M Ibrahim; Ebtsam M El-Kady; Somiaa A Eissa; Ahmed F Wahby
Journal:  J Adv Res       Date:  2015-03-21       Impact factor: 10.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.